keyword
MENU ▼
Read by QxMD icon Read
search

radionuclide therapy

keyword
https://www.readbyqxmd.com/read/29333576/bone-radionuclide-therapy-and-increased-survival-with-radium-223-is-the-way-to-go-for-nuclear-medicine-the-offer-that-oncologists-cannot-refuse
#1
EDITORIAL
Roberto C Delgado Bolton, Francesco Giammarile
No abstract text is available yet for this article.
January 14, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29333565/manual-on-the-proper-use-of-lutetium-177-labeled-somatostatin-analogue-lu-177-dota-tate-injectable-in-radionuclide-therapy-2nd-ed
#2
Makoto Hosono, Hideharu Ikebuchi, Yoshihide Nakamura, Nobutaka Nakamura, Takahiro Yamada, Sachiko Yanagida, Asami Kitaoka, Kiyotaka Kojima, Hiroyasu Sugano, Seigo Kinuya, Tomio Inoue, Jun Hatazawa
Here we present the guideline for the treatment of neuroendocrine tumors using Lu-177-DOTA-TATE on the basis of radiation safety aspects in Japan. This guideline was prepared by a study supported by Ministry of Health, Labour, and Welfare, and approved by Japanese Society of Nuclear Medicine. Lu-177-DOTA-TATE treatment in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown in this guideline are considered internationally useful as well...
January 15, 2018: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/29333464/comparison-of-tof-pet-and-bremsstrahlung-spect-images-of-yttrium-90-a-monte-carlo-simulation-study
#3
Akihiko Takahashi, Kazuhiko Himuro, Shingo Baba, Yasuo Yamashita, Masayuki Sasaki
Objectives: Yttrium-90 (90Y) is a beta particle nuclide used in targeted radionuclide therapy which is available to both single-photon emission computed tomography (SPECT) and time-of-flight (TOF) positron emission tomography (PET) imaging. The purpose of this study was to assess the image quality of PET and Bremsstrahlung SPECT by simulating PET and SPECT images of 90Y using Monte Carlo simulation codes under the same conditions and to compare them. Methods: In-house Monte Carlo codes, MCEP-PET and MCEP-SPECT, were employed to simulate images...
2018: Asia Oceania Journal of Nuclear Medicine & Biology
https://www.readbyqxmd.com/read/29331677/identification-of-potential-mr-derived-biomarkers-for-tumor-tissue-response-to-177lu-octreotate-therapy-in-an-animal-model-of-small-intestine-neuroendocrine-tumor
#4
Mikael Montelius, Johan Spetz, Oscar Jalnefjord, Evelin Berger, Ola Nilsson, Maria Ljungberg, Eva Forssell-Aronsson
Magnetic resonance (MR) methods enable noninvasive, regional tumor therapy response assessment, but associations between MR parameters, underlying biology, and therapeutic effects must be investigated. The aim of this study was to investigate response assessment efficacy and biological associations of MR parameters in a neuroendocrine tumor (NET) model subjected to radionuclide treatment. Twenty-one mice with NETs received 177Lu-octreotate at day 0. MR experiments (day -1, 1, 3, 8, and 13) included T2-weighted, dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) and relaxation measurements (T1/T2*)...
January 10, 2018: Translational Oncology
https://www.readbyqxmd.com/read/29331524/strategies-and-technical-challenges-for-imaging-oligometastatic-disease-recommendations-from-the-european-organisation-for-research-and-treatment-of-cancer-imaging-group
#5
REVIEW
Nandita M deSouza, Yan Liu, Arturo Chiti, Daniela Oprea-Lager, Géraldine Gebhart, Bernard E Van Beers, Ken Herrmann, Frederic E Lecouvet
Patients with oligometastatic disease (OMD) often have controllable symptoms, and cures are possible. Technical improvements in surgery and radiotherapy have introduced the option of metastasis-directed ablative therapies as an adjunct or alternative to standard-of-care systemic therapies. Several clinical trials and registries are investigating the benefit of these therapeutic approaches across several cancer sites. This requires that patients are correctly included and followed with appropriate imaging. This article discusses the evidence and offers recommendations for the implementation of standard-of-care (Response Evaluation Criteria in Solid Tumours measurements on computed tomography [CT], magnetic resonance imaging [MRI] and bone scintigraphy) and advanced imaging modalities (functional, metabolic and radionuclide targeted) for identifying and following up patients with OMD...
January 10, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29322344/deadtime-effects-in-quantification-of-177lu-activity-for-radionuclide-therapy
#6
Carlos F Uribe, Pedro L Esquinas, Marjorie Gonzalez, Wei Zhao, Jesse Tanguay, Anna Celler
BACKGROUND: The aim of this study was to investigate the deadtime (DT) effects that are present in 177Lu images acquired after radionuclide therapy injection, assess differences in DT based on the full spectrum and the photopeak-only measurements, and design a method to correct for the deadtime losses. A Siemens SymbiaT SPECT/CT camera with a medium energy collimator was used. A 295-mL bottle was placed off-center inside a large cylinder filled with water, and 177Lu activity was sequentially added up to a maximum of 9...
January 11, 2018: EJNMMI Physics
https://www.readbyqxmd.com/read/29322210/correction-to-dosimetry-in-clinical-radionuclide-therapy-the-devil-is-in-the-detail
#7
Francesco Giammarile, Kristoff Muylle, Roberto Delgado Bolton, Jolanta Kunikowska, Uwe Haberkorn, Wim Oyen
The above article which was published in Volume 44/ Issue 12 has incorrect page numbers. Instead of 1-3, it should have been 2137-2139.
January 11, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29320333/prostate-specific-membrane-antigen-pet-clinical-utility-in-prostate-cancer-normal-patterns-pearls-and-pitfalls
#8
Michael S Hofman, Rodney J Hicks, Tobias Maurer, Matthias Eiber
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed in prostate cancer. Radiolabeled small molecules that bind with high affinity to its active extracellular center have emerged as a potential new diagnostic standard of reference for prostate cancer, resulting in images with extraordinary tumor-to-background contrast. Currently, gallium 68 (68Ga)-PSMA-11 (or HBED-PSMA) is the most widely used radiotracer for PSMA positron emission tomography (PET)/computed tomography (CT) or PSMA PET/magnetic resonance (MR) imaging...
January 2018: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29315139/-dtpa-pabn-leu5-des-acyl-ghrelin-1-5-as-a-new-carrier-of-radionuclides-and-potential-precursor-of-radiopharmaceuticals
#9
Grzegorz Wójciuk, Marcin Kruszewski
BACKGROUND: Ghrelin is a peptide consisting of 28 aminoacids and an octadecyl side chain (acyl group) binding to the growth hormone secretagogue receptor type 1a (GHS-R1a). Its des-acylated form, des-acyl ghrelin (DAG) binds to the corticotropin releasing factor receptor type 2a (CRF2a) located on endocrine cancer cells such as the prostate carcinoma cell line DU 145. AIM: The aim of this study is to develop a new DAG-based carrier of radionuclides with potential application in therapy...
January 8, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29315138/peptide-receptor-radionuclide-therapy-with-177lu-dota-octreotate-dosimetry-nephrotoxicity-and-the-effect-of-hematological-toxicity-on-survival
#10
Anastassia Löser, Sarah M Schwarzenböck, Martin Heuschkel, Holger S Willenberg, Bernd J Krause, Jens Kurth
OBJECTIVES: Peptide receptor radionuclide therapy (PRRT) with lutetium-177 (Lu)-DOTATATE is regarded as a safe treatment option with promising results for patients with neuroendocrine neoplasia (NEN). We aimed to study the absorbed organ and tumor doses, the renal and hematological toxicity as well as their mutual interaction. Another aim was the identification of adverse effects as possible predictors which may affect survival. METHODS: A total of 30 (14 female and 16 male) patients with inoperable/metastatic NEN were treated with 7...
January 8, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29311408/hepatic-hydrothorax
#11
Yong Lv, Guohong Han, Daiming Fan
Hepatic hydrothorax (HH) is a pleural effusion that develops in a patient with cirrhosis and portal hypertension in the absence of cardiopulmonary disease. Although the development of HH remains incompletely understood, the most acceptable explanation is that the pleural effusion is a result of a direct passage of ascitic fluid into the pleural cavity through a defect in the diaphragm due to the raised abdominal pressure and the negative pressure within the pleural space. Patients with HH can be asymptomatic or present with pulmonary symptoms such as shortness of breath, cough, hypoxemia, or respiratory failure associated with large pleural effusions...
December 27, 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/29301755/copper-64-labeled-daratumumab-as-a-pet-ct-imaging-tracer-for-multiple-myeloma
#12
Enrico Caserta, Junie Chea, Megan Minnix, Domenico Viola, Steven Vonderfecht, Paul Yazaki, Desiree Crow, Jihane Khalife, James F Sanchez, Joycelynne M Palmer, Susanta Hui, Nadia Carlesso, Jonathan Keats, Young Kim, Ralf Buettner, Guido Marcucci, Steven Rosen, John Shively, David Colcher, Amrita Krishnan, Flavia Pichiorri
As a growing number of patients with multiple myeloma (MM) respond to upfront therapies while eventually relapsing in a time frame that is often non-predictable, attention has increasingly focused on developing novel diagnostic criteria to also account for disease dissemination. Positron emission tomography/computed tomography (PET/CT) is often used as a non-invasive monitoring strategy to assess cancer cell dissemination, but because the uptake of the currently used radiotracer 18fluoro-deoxyglucose (18F-FDG) is a function of the metabolic activity of both malignant and non-malignant cells, results frequently lack sufficient specificity...
January 4, 2018: Blood
https://www.readbyqxmd.com/read/29299370/safety-of-selective-internal-radiation-therapy-sirt-with-yttrium-90-microspheres-combined-with-systemic-anticancer-agents-expert-consensus
#13
REVIEW
Andrew Kennedy, Daniel B Brown, Jonas Feilchenfeldt, John Marshall, Harpreet Wasan, Marwan Fakih, Peter Gibbs, Alexander Knuth, Bruno Sangro, Michael C Soulen, Gianfranco Pittari, Ricky A Sharma
Selective internal radiation therapy (SIRT) with microspheres labelled with the β-emitter yttrium-90 (Y-90) enables targeted delivery of radiation to hepatic tumors. SIRT is primarily used to treat inoperable primary or metastatic liver tumors. Eligible patients have usually been exposed to a variety of systemic anticancer therapies, including cytotoxic agents, targeted biologics, immunotherapy and peptide receptor radionuclide therapy (PRRT). All these treatments have potential interactions with SIRT; however, robust evidence on the safety of these potential combinations is lacking...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29290808/dosimetric-evaluation-of-radionuclides-for-vcam-1-targeted-radionuclide-therapy-of-early-brain-metastases
#14
Nadia Falzone, Nicole L Ackerman, Liset de la Fuente Rosales, Mario A Bernal, Xiaoxuan Liu, Sarah Gja Peeters, Manuel Sarmiento Soto, Aurélien Corroyer-Dulmont, Myriam Bernaudin, Elisa Grimoin, Omar Touzani, Nicola R Sibson, Katherine A Vallis
Brain metastases develop frequently in patients with breast cancer, and present a pressing therapeutic challenge. Expression of vascular cell adhesion molecule 1 (VCAM-1) is upregulated on brain endothelial cells during the early stages of metastasis and provides a target for the detection and treatment of early brain metastases. The aim of this study was to use a model of early brain metastasis to evaluate the efficacy of α-emitting radionuclides, 149Tb, 211At, 212Pb, 213Bi and 225Ac; β-emitting radionuclides, 90Y, 161Tb and 177Lu; and Auger electron (AE)-emitters 67Ga, 89Zr, 111In and 124I, for targeted radionuclide therapy (TRT)...
2018: Theranostics
https://www.readbyqxmd.com/read/29286506/photodynamic-therapy-effect-on-healing-of-radiation-skin-ulcer-infected-with-pseudomonas-aeruginosa
#15
N V Krasnoselskiy, L I Simonova, V Z Gertman, E S Pushkar
OBJECTIVE: To reveal the effect of photodynamic therapy on the healing of experimental radiation skin ulcers infect ed with Pseudomonas aeruginosa. MATERIALS AND METHODS: The infected radionuclide was modeled by local X ray irradiation of the rat's hip skin at a dose of 85.0 Gy, followed by the application of Pseudomonas aeruginosa bacterial suspension to the surface of the ulcer. Photodynamic therapy (CTD) was performed with the help of a photon apparatus «Barva LED/630» and a photosen sitizer of methylene blue...
December 2017: Problemy Radiat︠s︡iĭnoï Medyt︠s︡yny Ta Radiobiolohiï
https://www.readbyqxmd.com/read/29286003/135la-as-an-auger-electron-emitter-for-targeted-internal-radiotherapy
#16
J Fonslet, B Q Lee, T A Tran, M Siragusa, M Jensen, T Kibédi, A E Stuchbery, G W Severin
135La has favorable nuclear and chemical properties for Auger-based targeted internal radiotherapy. Here we present detailed investigations of the production, emissions, and dosimetry related to 135La therapy. 135La was produced by 16.5 MeV proton irradiation of metallic natBa on a medical cyclotron, and was isolated and purified by trap-and-release on weak cation-exchange resin. The average production rate was 407  ±  19 MBq µA-1 (saturation activity), and the radionuclidic purity was 98% at 20 h post irradiation...
December 29, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/29284590/peptide-receptor-radionuclide-therapy-as-neoadjuvant-therapy-for-resectable-or-potentially-resectable-pancreatic-neuroendocrine-neoplasms
#17
Stefano Partelli, Emilio Bertani, Mirco Bartolomei, Carolina Perali, Francesca Muffatti, Chiara Maria Grana, Marco Schiavo Lena, Claudio Doglioni, Stefano Crippa, Nicola Fazio, Giuseppe Zamboni, Massimo Falconi
BACKGROUND: Peptide receptor radionuclide therapy is a valid therapeutic option for pancreatic neuroendocrine neoplasms. The aim of this study was to describe an initial experience with the use of peptide receptor radionuclide therapy as a neoadjuvant agent for resectable or potentially resectable pancreatic neuroendocrine neoplasms. METHODS: The postoperative outcomes of 23 patients with resectable or potentially resectable pancreatic neuroendocrine neoplasms at high risk of recurrence who underwent neoadjuvant peptide receptor radionuclide therapy (peptide receptor radionuclide therapy group) were compared with 23 patients who underwent upfront surgical operation (upfront surgery group)...
December 25, 2017: Surgery
https://www.readbyqxmd.com/read/29283383/targeted-%C3%AE-therapies-for-the-treatment-of-bone-metastases
#18
REVIEW
Fable Zustovich, Roberto Barsanti
The skeleton is the target tissue for many types of tumors, and, recently, the survival of patients with prostate cancer metastasis has been increased using α-emitting drugs known as targeted α therapies. The use of α-radiopharmaceuticals in medicine was hypothesized at the beginning of the nineteenth century after the observation that α-radionuclides were associated with high cell-killing energy and low tissue penetration in healthy tissues. In the prostate cancer (PC) scenario, current research suggests that this class of radiopharmaceuticals has limited toxicity, and that the mechanism of action does not overlap with pre-existing drugs, allowing us to extend therapeutic armaments and address medical oncology towards personalized and precision medicine...
December 28, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29278583/prostate-specific-membrane-antigen-theranostics-therapy-with-lutetium-177
#19
Justin Ferdinandus, John Violet, Shahneen Sandhu, Michael S Hofman
PURPOSE OF REVIEW: Prostate-specific membrane antigen (PSMA) theranostics offers a new approach for a personalized and targeted treatment for metastatic prostate cancer. Lutetium-177-labelled PSMA-ligands (Lu-PSMA) is a radionuclide therapy that is directed to PSMA expressing prostate cancer. Clinical experience with Lu-PSMA in men with advanced prostate cancer is growing. The purpose of this review is to outline the mechanism of action of this therapy, summarize recent efficacy and toxicity data and highlight future direction and challenges in establishing Lu-PSMA treatment as part of routine clinical practice...
December 22, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/29277438/hazardous-parameters-associated-with-natural-radioactivity-exposure-from-black-sand
#20
M A Hilal, E H Borai
Black sand samples collected from Baltim beaches (Kafr El-Sheikh governorate) in Egypt on the Mediterranean Sea shore were analyzed radiometrically and evaluated using a nondestructive gamma ray spectroscopic techniques. The natural radionuclides of 226Ra, 232Th and 40K in the black sand samples were identified and quantified. It is found that the activity concentrations for 226Ra, 232Th and 40K in different eleven sites (S1S11) were found within the ranges of 28-322, 91-308 and 81-339 Bq/kg, respectively. Moreover, different radiological hazardous parameters (absorbed dose rate, annual effective dose equivalent, radium activity, annual gonadal dose equivalent and excess lifetime cancer risk) were calculated...
December 22, 2017: Regulatory Toxicology and Pharmacology: RTP
keyword
keyword
100899
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"